Clark Enterprises-backed Verax Biomedical Raises over Half of $5 Million Mixed Offering


By Bill Murphy

Verax Biomedical Inc., which has developed technology to enable rapid blood tests, has raised $2.78 million, or over 55 percent of a mixed offering of $5 million, from 11 investors, according to an SEC filing.

Principals named in the filing by the Worcester, Mass.-based firm are the following executives:

?         CEO James Lousararian;
?         Joe Sanders, senior vice president for Marketing and Business Development;
?         Nancy Hornbaker, vice president for Regulatory Affairs;
?         R. Scott McKenzie, senior vice president of Operations; and
        Greg Lawrence, vice president for Research and Development.

Also named in the filing were the following directors;

?         Buzz Benson of Minneapolis-based SightLine Partners;
?         Joe Del Guercio of Bethesda, Md.-based Clark Enterprises Inc.;
?         Marc Goldberg of Boston-based Bioventures Investors;
?         James Koziarz of Midwest Venture Partners; and
?         Robert Zieserl of Highland Park, Ill.-based KB Partners.

Lousararian, who began consulting with Verax in the fall of 2005, was named the CEO in February 2006. Prior to joining Verax, he was a consultant for Medtronic Vascular, following that company?s acquisition of Angiolink Corp. in November 2004. Lousararian previously co-founded and led a life sciences startup, AngioLink.

Verax Biomedical enables rapid tests to detect bacterial contaminants in blood components, tissues for transplantation and cellular therapies.

Stories you Need to Know

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.